Are there any contraindications to teriparatide injection?

Teriparatide injection (Teriparatide) is a drug used to treat osteoporosis. It promotes bone formation and increases bone density by simulating the effects of parathyroid hormone, thereby reducing the risk of fractures. However, despite its significant efficacy in treating osteoporosis, teriparatide is not suitable for all patients. Certain conditions or circumstances may contraindicate the use of teriparatide. The following are the main contraindications to this drug.

1. Patients with hypercalcemia

Hypercalcemia is a contraindication to teriparatide. Patients who already have hypercalcemia, which is a concentration of calcium in the blood that exceeds normal levels, should not take teriparatide. Teriparatide may cause an increase in blood calcium levels by stimulating bone formation and releasing calcium into the blood. If the patient already has hypercalcemia, continued use of teriparatide may aggravate this symptom, increase the calcium ion burden, further worsen hypercalcemia, and cause serious health problems, such as kidney stones, heart problems (such as arrhythmia), etc. Therefore, before starting treatment, the patient's blood calcium level must be tested to ensure that the blood calcium is within the normal range.

2. Patients with active bone tumors

Teriparatide should also be avoided in patients with active bone tumors. Teriparatide, a drug that promotes bone formation, may stimulate tumor growth or accelerate the spread of tumors. Although teriparatide is used to treat osteoporosis, use of this drug may adversely affect the condition if a patient's bones have been affected by bone tumors or have signs of cancer that has metastasized to the bones. For patients with a history of bone tumors, especially known primary malignant bone tumors, a full evaluation should be conducted before using teriparatide, and a professional physician should decide whether this drug is suitable for use based on the patient's specific conditions.

3. Osteosarcoma patients

Osteosarcoma is a malignant bone tumor that usually occurs in adolescents or young adults. Clinical data with teriparatide suggest that long-term use of the drug may increase the risk of osteosarcoma, although this risk is very low. In animal experiments, teriparatide has been found to be associated with the development of osteosarcoma, especially when used long-term or at high doses. Therefore, teriparatide injection is not recommended for patients with osteosarcoma or a family history of osteosarcoma. Patients should avoid using this drug if they have had or currently have any form of bone tumor, especially osteosarcoma.

4. Patients with severe renal insufficiency

Severe renal insufficiency is also a contraindication to the use of teriparatide. Although teriparatide can still be used in patients with mild or moderate renal impairment, there are certain risks associated with its use in patients with severely impaired renal function. The metabolism of teriparatide is mainly carried out by the kidneys. Patients with renal insufficiency may affect the clearance of the drug, causing the drug to accumulate in the body, thus increasing the risk of side effects, especially problems such as hypercalcemia and hypercalciuria. For patients with extremely poor renal function, the use of teriparatide should be avoided to avoid increasing the burden on the kidneys and causing adverse reactions.

5. Pregnant and lactating women

The safety of teriparatide in pregnant and nursing women has not been well studied, therefore, pregnant and nursing women should not use this drug. In animal experiments, there are no clear conclusions on the effects of teriparatide on embryos or fetuses, but considering the potential risks, especially in the early stages of pregnancy, it is a conservative approach to avoid using the drug. If women who are pregnant or planning to become pregnant require treatment for osteoporosis, they should seek other, safer treatments. It is not known whether teriparatide is excreted in breast milk during breastfeeding, and therefore, breastfeeding women should avoid using this drug.

6. Patients with a history of severe allergic reactions

For those patients with a history of severe allergic reactions (such as anaphylactic shock, laryngeal edema, rash, dyspnea, etc.), the use of teriparatide may cause severe allergic reactions. Although allergic reactions to teriparatide injection are rare, any drug may trigger an allergy in some sensitive individuals. Particularly if the patient has a history of allergy to teriparatide or any of its components, this medication must be used with extreme caution. Before use, patients should inform their doctor if they have any allergies so that the doctor can evaluate the risks and benefits of drug use.

7. The elderly and patients with a history of fractures

Although teriparatide is primarily used to treat osteoporosis, some older adults and patients with a history of multiple fractures may need special attention when using teriparatide. Elderly patients may be more fragile in terms of bone metabolism and may be more sensitive to adverse drug reactions. Therefore, when using teriparatide in elderly patients, doctors need to comprehensively consider the patient's physical condition, bone density, fracture history and other health factors to ensure the safe use of the drug.

8. Other notes

In some special circumstances, the use of teriparatide may require additional caution. For example, for patients with a history of diabetes, especially type 1 diabetes, teriparatide may affect bone metabolism and blood sugar levels, so blood sugar changes need to be closely monitored during use. In addition, when teriparatide is used in combination with other drugs, drug interactions may occur, affecting the efficacy of the drug or causing side effects. Therefore, before starting treatment with teriparatide, patients should inform their physician of all medications they are taking, including prescription, over-the-counter, and herbal medicines, so that the physician can evaluate possible drug interactions.

Although teriparatide injection has achieved remarkable results in treating osteoporosis, it is not suitable for all patients. Hypercalcemia, active bone tumors, osteosarcoma, severe renal insufficiency, pregnant and lactating women, and patients with a history of severe allergic reactions should avoid using this drug. Before use, patients should conduct a comprehensive health assessment and fully communicate with their doctor to ensure the safety of treatment. If the patient experiences any adverse reactions or changes in health status during use, he should contact his doctor in time to adjust the treatment plan.